Continuous vs. Cyclical Hormone Therapy: Does Estrogen Need Time Without Progesterone?

It is common to hear that estrogen needs to be taken “unopposed” for part of each month so that progesterone does not suppress its benefits. However, current menopause research does not show that women must regularly stop progesterone—or take estrogen alone—to receive the benefits of hormone therapy.
​
Both continuous combined hormone therapy and cyclical hormone therapy are established approaches. The appropriate schedule depends on factors such as a woman’s stage of menopause, whether she has a uterus, her bleeding pattern, her symptoms, and the formulation prescribed.
​

With continuous combined therapy, estrogen and progesterone or another progestogen are taken together on an ongoing basis.
Estrogen is used to support symptoms and tissues affected by declining estrogen levels. Progesterone is included primarily to protect the uterine lining in women who still have a uterus.
Continuous therapy is commonly used after menopause because it can provide consistent hormone exposure without intentionally creating a monthly withdrawal bleed. Reviews of continuous combined therapy describe it as a way to maintain the benefits of hormone treatment while avoiding the scheduled bleeding commonly associated with cyclical regimens.
​

With cyclical, or sequential, therapy:
​

This approach is often used during perimenopause or closer to the final menstrual period, particularly when a woman is still experiencing natural menstrual cycles.
A withdrawal bleed does not necessarily mean that cyclical therapy is more effective. It is primarily a consequence of changing progesterone exposure.
​

There is no established clinical requirement for a woman to take estrogen without progesterone for one or two weeks each month in order for estrogen to work.
Research and clinical guidance recognize that combined hormone therapy can:
​

A review specifically addressing the role of progestogens explains that the goal of combined therapy is to protect the endometrium while maintaining estrogen’s benefits, not to eliminate them.
Clinical trials of continuous combined regimens have also found improvement in menopausal symptoms and preservation of bone mineral density while progesterone or a progestogen was administered continuously.
Progesterone and estrogen can have different or sometimes opposing effects in particular tissues. That does not mean progesterone broadly “cancels out” estrogen throughout the body.
​

Systemic estrogen stimulates the endometrium, which is the tissue lining the uterus. When systemic estrogen is used without adequate progesterone, the lining may continue to grow, increasing the risk of endometrial hyperplasia and endometrial cancer.
Progesterone changes and stabilizes the endometrium, helping prevent excessive estrogen-driven growth. Modern reviews describe endometrial protection as the central reason progesterone or another progestogen is included in systemic hormone therapy for women with a uterus.
For this reason, deliberately creating repeated periods of unopposed systemic estrogen is not generally considered necessary—and may be inappropriate—unless a clinician has prescribed a specific regimen.
​

Several studies indexed in PubMed support the endometrial safety of appropriately prescribed continuous combined hormone therapy.
​

One long-term study evaluated continuous estrogen-progestin combinations in postmenopausal women. Both continuous progestin doses prevented estrogen-related stimulation of the uterine lining, and no endometrial hyperplasia was observed in the treatment groups. Participants also maintained or increased bone mineral density.
​

A one-year study examined a continuous combined estradiol and norethisterone patch in postmenopausal women with an intact uterus. The study was specifically designed to evaluate endometrial protection and the incidence of hyperplasia or cancer during treatment.
​

A population-based study found that the risk of endometrial cancer was low among women using continuous combined hormone therapy compared with women who did not use hormones.
​

Another study examining women using long-term continuous combined therapy found that most had an inactive endometrium. The authors concluded that the regimen appeared safe with respect to endometrial health, while also emphasizing that ongoing clinical follow-up remains important.
These studies do not mean that every dose, route, or formulation is interchangeable. Endometrial protection depends on receiving enough progesterone relative to the amount of estrogen being used.
​

Neither schedule is automatically best for every woman.
​Cyclical therapy may be preferred when:
​

Continuous combined therapy may be preferred when:
​

Clinical prescribing guidance recognizes continuous combined hormone therapy as an established option and notes that it may provide more effective endometrial protection than sequential treatment in appropriate postmenopausal patients.
​

A monthly withdrawal bleed is not required for the uterus to remain healthy during properly balanced continuous combined hormone therapy.
With continuous treatment, progesterone generally helps keep the endometrium thin and inactive rather than allowing it to build up and then shed every month.
Bleeding can still occur during the first several months of treatment while the body adjusts. However, new, heavy, persistent, or unexplained bleeding should always be reviewed by a healthcare professional—especially after a period of established amenorrhea.
​

Oestra® provides estradiol and micronized progesterone together. The progesterone is included to support appropriate balance and uterine protection for women who have a uterus.
There is not currently a large published clinical trial evaluating every specific compounded vaginal estradiol-progesterone formulation. Therefore, research involving oral, transdermal, and other continuous combined regimens cannot be treated as direct proof for every compounded product or dose.
However, the broader evidence does support the clinical principle behind continuous combined therapy: estrogen can continue to provide therapeutic benefits when progesterone is taken at the same time, and a scheduled period of unopposed estrogen is not required.
Patients should follow the schedule prescribed by their Inner Balance provider rather than independently stopping progesterone, changing their dose, or creating an estrogen-only portion of the month.
​

Continuous and cyclical hormone therapy are both recognized treatment approaches. Current evidence does not support the claim that estrogen must be taken without progesterone for part of every month to preserve its benefits.
For women with a uterus, adequate progesterone is an important part of safely using systemic estrogen. When continuous combined therapy is appropriately prescribed, research supports its ability to relieve menopausal symptoms, protect bone health, and protect the uterine lining without requiring a scheduled monthly bleed.
Hormone therapy should always be individualized. Questions about bleeding, dosing, side effects, or whether a continuous or cyclical schedule is most appropriate should be reviewed with the clinical team.
​
Sources
​